Sequential Skin: Revolutionising atopic dermatitis diagnosis through a novel skin microbiome test.

特应性皮炎(AD)是一种多因素慢性和复发性炎症性皮肤病，影响五分之一的英国儿童和十分之一的成年人。29%是中/重度病例--仅在英国就有超过197万患者受到影响--医疗保健和社会经济成本每年超过7.23亿GB。由于没有确定的治疗方法，管理AD发病/进展的重大治疗挑战来自：*各种AD条件/病因的复杂性*许多不同的患者群体*跨不同治疗和配方的1000多条潜在治疗途径。然而，现有诊断方法有效告知/针对这些现有治疗方法的能力有限。此外，尽管最近的研究表明，患者的皮肤微生物组可以指示疾病进展，但没有实用的临床工具来进行精确的皮肤微生物组分析，防止新出现的个性化AD药物/治疗的患者分层。因此，治疗路径(NHS/Private)在多次就诊时反复尝试，未能充分：*缓解症状*将副作用降至最低*缓解疾病进展。Sequential Skin Ltd已经推出了一种破坏性的消费者皮肤测试，用于美容皮肤健康应用，基于专利：*分析关键细菌微生物组标记，以及基因测序*用于非侵入性皮肤采样的贴片，已经实现了比现有棉签和剥离黄金标准显著更高的收集效率*与其他直接面向消费者的基因测试公司相比，实验室流程将皮肤分子结果的时间缩短了75%利用突破性研究证明了使用微生物DNA生物标记物簇改进了对AD进展的预测，Sequential Skin现在的目标是将这些开发扩展到临床领域，目标是第一个针对患者特定AD简档和治疗预后的非侵入性临床生物信息解决方案。

Atopic dermatitis (AD) is a multifactorial chronic and recurrent inflammatory skin disease, affecting 1-in-5 UK children and 1-in-10 adults. Circa.29% are moderate/severe cases -- affecting over 1.97million patients in the UK alone -- with healthcare and socio-economic costs exceeding £723million annually.With no definitive cure, a significant therapeutic challenge to manage AD flare-ups/progression arises from:* Complexity across varied AD conditions/pathogeneses* Many disparate patient populations* Over 1000 potential therapeutic pathways across different treatments and formulationsHowever, capability of incumbent diagnostic approaches to effectively inform/target these existing treatments is limited.Furthermore, whilst recent research demonstrates that patients' skin microbiome can dictate disease progression, no practical clinical tool for precision skin microbiome analysis exists, preventing patient stratification for emerging personalised AD medicines/treatments.Consequently, treatment pathways (NHS/private) are trial-and-error over multiple visits, failing to adequately:* Relieve symptoms* Minimise side effects* Mitigate disease progression.Sequential Skin Ltd have already introduced a disruptive consumer skin-test for cosmetic skin health applications, based on proprietary:* Analysis of key bacterial microbiome-markers, alongside genetic sequencing* Patches for non-invasive skin sampling, already achieving significantly higher collection efficiency than existing swabs and tape-stripping gold-standards* Laboratory processes reducing time-around for skin molecular results by 75% with respect to other direct-to-consumer genetic testing companiesLeveraging breakthrough research demonstrating improved prediction of AD progression using microbial DNA biomarker clusters, Sequential Skin now aim to extend these developments into the clinical domain, targeting the first non-invasive clinical bioinformatic solution for patient-specific AD profiling and treatment prognosis.